These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 16139468)

  • 1. Adherence and perception of medication in patients with chronic heart failure during a five-year randomised trial.
    Ekman I; Andersson G; Boman K; Charlesworth A; Cleland JG; Poole-Wilson P; Swedberg K
    Patient Educ Couns; 2006 Jun; 61(3):348-53. PubMed ID: 16139468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.
    Jabbour A; Macdonald PS; Keogh AM; Kotlyar E; Mellemkjaer S; Coleman CF; Elsik M; Krum H; Hayward CS
    J Am Coll Cardiol; 2010 Apr; 55(17):1780-7. PubMed ID: 20413026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exchange of beta-blockers in heart failure patients. Experiences from the poststudy phase of COMET (the Carvedilol or Metoprolol European Trial).
    Di Lenarda A; Remme WJ; Charlesworth A; Cleland JG; Lutiger B; Metra M; Komajda M; Torp-Pedersen C; Scherhag A; Swedberg K; Poole-Wilson PA;
    Eur J Heart Fail; 2005 Jun; 7(4):640-9. PubMed ID: 15921806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adherence with once daily versus twice daily carvedilol in patients with heart failure: the Compliance And Quality of Life Study Comparing Once-Daily Controlled-Release Carvedilol CR and Twice-Daily Immediate-Release Carvedilol IR in Patients with Heart Failure (CASPER) Trial.
    Udelson JE; Pressler SJ; Sackner-Bernstein J; Massaro J; Ordronneau P; Lukas MA; Hauptman PJ
    J Card Fail; 2009 Jun; 15(5):385-93. PubMed ID: 19477398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of carvedilol or metoprolol on PAI-1, tPA-mass concentration or Von Willebrand factor in chronic heart failure--a COMET substudy.
    Boman K; Jansson JH; Nilsson T; Swedberg K; Cleland JG; Poole-Wilson P
    Thromb Res; 2010 Feb; 125(2):e46-50. PubMed ID: 19762071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic importance of plasma NT-pro BNP in chronic heart failure in patients treated with a beta-blocker: results from the Carvedilol Or Metoprolol European Trial (COMET) trial.
    Olsson LG; Swedberg K; Cleland JG; Spark PA; Komajda M; Metra M; Torp-Pedersen C; Remme WJ; Scherhag A; Poole-Wilson P;
    Eur J Heart Fail; 2007 Aug; 9(8):795-801. PubMed ID: 17693380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET.
    Swedberg K; Olsson LG; Charlesworth A; Cleland J; Hanrath P; Komajda M; Metra M; Torp-Pedersen C; Poole-Wilson P
    Eur Heart J; 2005 Jul; 26(13):1303-8. PubMed ID: 15767288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of carvedilol and metoprolol on the mode of death in patients with heart failure.
    Remme WJ; Cleland JG; Erhardt L; Spark P; Torp-Pedersen C; Metra M; Komajda M; Moullet C; Lukas MA; Poole-Wilson P; Di Lenarda A; Swedberg K
    Eur J Heart Fail; 2007 Nov; 9(11):1128-35. PubMed ID: 17716943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A randomized comparison of carvedilol and metoprolol in patients with chronic heart failure. The Carvedilol Or Metoprolol European Trial (COMET) ].
    Torp-Pedersen CT;
    Ugeskr Laeger; 2004 Aug; 166(32):2671-4. PubMed ID: 15347171
    [No Abstract]   [Full Text] [Related]  

  • 10. A comparison of the effects of carvedilol and metoprolol on well-being, morbidity, and mortality (the "patient journey") in patients with heart failure: a report from the Carvedilol Or Metoprolol European Trial (COMET).
    Cleland JG; Charlesworth A; Lubsen J; Swedberg K; Remme WJ; Erhardt L; Di Lenarda A; Komajda M; Metra M; Torp-Pedersen C; Poole-Wilson PA;
    J Am Coll Cardiol; 2006 Apr; 47(8):1603-11. PubMed ID: 16630997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Commentary on the Carvedilol or Metoprolol European Trial (COMET).
    Poole-Wilson PA
    Am J Cardiol; 2004 May; 93(9A):40B-2B. PubMed ID: 15144936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of chronic heart failure with carvedilol in daily practice: the SATELLITE survey experience.
    Lainscak M; Moullet C; Schön N; Tendera M
    Int J Cardiol; 2007 Nov; 122(2):149-55. PubMed ID: 17804098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The COMET study compares effect of two different beta-blockers in chronic heart failure. Carvedilol better than metoprolol].
    Swedberg K
    Lakartidningen; 2003 Sep; 100(37):2852-4. PubMed ID: 14558169
    [No Abstract]   [Full Text] [Related]  

  • 14. Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET.
    Remme WJ; Torp-Pedersen C; Cleland JG; Poole-Wilson PA; Metra M; Komajda M; Swedberg K; Di Lenarda A; Spark P; Scherhag A; Moullet C; Lukas MA
    J Am Coll Cardiol; 2007 Mar; 49(9):963-71. PubMed ID: 17336720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A description of the clinical characteristics at baseline of patients recruited into the Carvedilol or Metoprolol European Trial (COMET).
    Cleland JG; Goode K; Erhardt L; Remme WJ; Charlesworth A; Poole-Wilson PA; Di Lenarda A; Hanrath P; Komajda M; Metra M; Swedberg K; Torp-Pedersen C;
    Cardiovasc Drugs Ther; 2004 Mar; 18(2):139-52. PubMed ID: 15162076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are beta-blockers needed in patients receiving spironolactone for severe chronic heart failure? An analysis of the COPERNICUS study.
    Krum H; Mohacsi P; Katus HA; Tendera M; Rouleau JL; Fowler MB; Coats AJ; Roecker EB; Packer M;
    Am Heart J; 2006 Jan; 151(1):55-61. PubMed ID: 16368292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure--COMET.
    Torp-Pedersen C; Poole-Wilson PA; Swedberg K; Cleland JG; Di Lenarda A; Hanrath P; Komajda M; Lutiger B; Metra M; Remme WJ; Scherhag A; Skene A;
    Am Heart J; 2005 Feb; 149(2):370-6. PubMed ID: 15846279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sudden cardiac death risk factors in patients with heart failure treated with carvedilol.
    Nessler J; Nessler B; Kitliński M; Libionka A; Kubinyi A; Konduracka E; Piwowarska W
    Kardiol Pol; 2007 Dec; 65(12):1417-22; discussion 1423-4. PubMed ID: 18181053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial.
    Hori M; Sasayama S; Kitabatake A; Toyo-oka T; Handa S; Yokoyama M; Matsuzaki M; Takeshita A; Origasa H; Matsui K; Hosoda S;
    Am Heart J; 2004 Feb; 147(2):324-30. PubMed ID: 14760332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does atrial fibrillation in elderly patients with chronic heart failure limit the efficacy of carvedilol? Suggestions from an observational study.
    Opasich C; De Feo S; Cioffi G; Pulignano G; Del Sindaco D; Tarantini L; Gualco A; Patrignani A
    Ital Heart J; 2005 Apr; 6(4):323-7. PubMed ID: 15902931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.